Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cabaletta Bio Inc

Current price
10.67 USD -0.48 USD (-4.30%)
Last closed 10.92 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 527 179 392 USD
Yield for 12 month +8.55 %
21.11.2021 - 28.11.2021

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Address: 2929 Arch Street, Philadelphia, PA, United States, 19104

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

33.56 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

+4 010 000 USD

Current Year

-1 426 000 USD

Last Year

-3 684 000 USD

Current Quarter

-393 000 USD

Last Quarter

+3 674 000 USD

Key Figures CABA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -84 281 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -31.16 %
PEG Ratio
Return On Equity TTM -49.06 %
Wall Street Target Price 33.56 USD
Revenue TTM
Book Value 4.6 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.71 USD
Diluted Eps TTM -1.71 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CABA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CABA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CABA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -8.0024
Price Book MRQ 3.4813

Financials CABA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CABA

For 52 weeks

9.55 USD 26.35 USD
50 Day MA 14.5 USD
Shares Short Prior Month 10 248 978
200 Day MA 17.2 USD
Short Ratio 6.49
Shares Short 9 103 627
Short Percent 19.49 %

Dynamics of changes in the value of assets




430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds



14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics



2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics